Source: Google NewsPublished on 2023-05-24
Related Articles:
- Breast Cancer Awareness Month and Parkinson’s October 12, 2021 Optimism is the faith that leads to achievement. Nothing can be done without hope and confidence.Helen Keller Five years ago, in October 2016, I wrote about Breast Cancer vs Parkinsons, which turns out to be my most popular post since beginning this blog. It is still getting read almost daily by someone, somewhere. Since October is Breast Cancer Awareness Month,…
- Michigan Matters: Chevrolet Detroit Grand Prix Returns to Belle Isle, Detroit Tigers Great Kirk Gibson on Confronting Parkinson’s Disease - CBS Detroit June 4, 2021 Michigan Matters: Chevrolet Detroit Grand Prix Returns to Belle Isle, Detroit Tigers Great Kirk Gibson on Confronting Parkinson’s Disease CBS Detroit
- The Brilliant 10: The top up-and-coming minds in science October 19, 2022 Popular Science There’s a phrase that rings loudly in the heads of Popular Science editors any time we bring together a new Brilliant 10 class: “They’ve only just begun.” Our annual list of early-career scientists and engineers is as much a celebration of what our honorees have already accomplished as it is a forecast for what they’ll do next. To…
- Breast cancer in multiple endocrine neoplasia type 1 (MEN1) May 7, 2021 Endocrinol Diabetes Metab Case Rep. 2021 Apr 1;2021:EDM200196. doi: 10.1530/EDM-20-0196. Online ahead of print.ABSTRACTSUMMARY: A 38-year-old female was identified as carrying a heterozygous pathogenic MEN1 variant (c.1304delG) through predictive genetic testing, following a diagnosis of familial hyperparathyroidism. Routine screening for parathyroid and pituitary disease was negative. However, cross-sectional imaging by CT revealed a 41 mm pancreatic tail mass. Biopsy via…
- Breast cancer in multiple endocrine neoplasia type 1 (MEN1) May 7, 2021 Endocrinol Diabetes Metab Case Rep. 2021 Apr 1;2021:EDM200196. doi: 10.1530/EDM-20-0196. Online ahead of print.ABSTRACTSUMMARY: A 38-year-old female was identified as carrying a heterozygous pathogenic MEN1 variant (c.1304delG) through predictive genetic testing, following a diagnosis of familial hyperparathyroidism. Routine screening for parathyroid and pituitary disease was negative. However, cross-sectional imaging by CT revealed a 41 mm pancreatic tail mass. Biopsy via…
- Breast cancer in multiple endocrine neoplasia type 1 (MEN1) May 7, 2021 Endocrinol Diabetes Metab Case Rep. 2021 Apr 1;2021:EDM200196. doi: 10.1530/EDM-20-0196. Online ahead of print.ABSTRACTSUMMARY: A 38-year-old female was identified as carrying a heterozygous pathogenic MEN1 variant (c.1304delG) through predictive genetic testing, following a diagnosis of familial hyperparathyroidism. Routine screening for parathyroid and pituitary disease was negative. However, cross-sectional imaging by CT revealed a 41 mm pancreatic tail mass. Biopsy via…
- Breast cancer in multiple endocrine neoplasia type 1 (MEN1) May 7, 2021 Endocrinol Diabetes Metab Case Rep. 2021 Apr 1;2021:EDM200196. doi: 10.1530/EDM-20-0196. Online ahead of print.ABSTRACTSUMMARY: A 38-year-old female was identified as carrying a heterozygous pathogenic MEN1 variant (c.1304delG) through predictive genetic testing, following a diagnosis of familial hyperparathyroidism. Routine screening for parathyroid and pituitary disease was negative. However, cross-sectional imaging by CT revealed a 41 mm pancreatic tail mass. Biopsy via…
- Breast cancer in multiple endocrine neoplasia type 1 (MEN1) May 7, 2021 Endocrinol Diabetes Metab Case Rep. 2021 Apr 1;2021:EDM200196. doi: 10.1530/EDM-20-0196. Online ahead of print.ABSTRACTSUMMARY: A 38-year-old female was identified as carrying a heterozygous pathogenic MEN1 variant (c.1304delG) through predictive genetic testing, following a diagnosis of familial hyperparathyroidism. Routine screening for parathyroid and pituitary disease was negative. However, cross-sectional imaging by CT revealed a 41 mm pancreatic tail mass. Biopsy via…
- Breast cancer in multiple endocrine neoplasia type 1 (MEN1) May 7, 2021 Endocrinol Diabetes Metab Case Rep. 2021 Apr 1;2021:EDM200196. doi: 10.1530/EDM-20-0196. Online ahead of print.ABSTRACTSUMMARY: A 38-year-old female was identified as carrying a heterozygous pathogenic MEN1 variant (c.1304delG) through predictive genetic testing, following a diagnosis of familial hyperparathyroidism. Routine screening for parathyroid and pituitary disease was negative. However, cross-sectional imaging by CT revealed a 41 mm pancreatic tail mass. Biopsy via…
- Breast cancer in multiple endocrine neoplasia type 1 (MEN1) May 7, 2021 Endocrinol Diabetes Metab Case Rep. 2021 Apr 1;2021:EDM200196. doi: 10.1530/EDM-20-0196. Online ahead of print.ABSTRACTSUMMARY: A 38-year-old female was identified as carrying a heterozygous pathogenic MEN1 variant (c.1304delG) through predictive genetic testing, following a diagnosis of familial hyperparathyroidism. Routine screening for parathyroid and pituitary disease was negative. However, cross-sectional imaging by CT revealed a 41 mm pancreatic tail mass. Biopsy via…
- Dr. Roach: Violent nighttime movement likely REM sleep disorder - The Detroit News July 14, 2021 Dr. Roach: Violent nighttime movement likely REM sleep disorder The Detroit News
- Dr. Roach: Sister insists visitors to 95-year-old dad should be vaccinated - The Detroit News November 22, 2021 Dr. Roach: Sister insists visitors to 95-year-old dad should be vaccinated The Detroit News
- Dr. Roach: For coffee benefits, it doesn’t matter if it’s caffeinated or decaf - The Detroit News January 11, 2022 Dr. Roach: For coffee benefits, it doesn’t matter if it’s caffeinated or decaf The Detroit News
- Dr. Roach: The controversy over estrogen reduction and ED - Detroit News April 15, 2022 Dr. Roach: The controversy over estrogen reduction and ED Detroit News
- Dr. Roach: When it comes to starting a statin, it's not all in the numbers - Detroit News May 23, 2022 Dr. Roach: When it comes to starting a statin, it's not all in the numbers Detroit News
- Dr. Roach: Reader mystified by sudden allergic reactions - Detroit News May 26, 2022 Dr. Roach: Reader mystified by sudden allergic reactions Detroit News
- Clinical Significance of Receptor-Interacting Protein 3 and Parkin, Essential Molecules for Necroptosis, in Breast Cancer February 26, 2021 J Breast Cancer. 2021 Feb;24(1):34-48. doi: 10.4048/jbc.2021.24.e12.ABSTRACTPURPOSE: Receptor-interacting protein 3 (RIP3) is the main initiator of necroptosis. Parkin prevents the formation of the RIP1-RIP3 complex by promoting polyubiquitination of RIP3. However, the mechanism by which necroptosis affects the clinical features of breast cancer and prognosis is not known. Here, we aimed to study the effect of necroptosis on the clinical…
- Clinical Significance of Receptor-Interacting Protein 3 and Parkin, Essential Molecules for Necroptosis, in Breast Cancer February 26, 2021 J Breast Cancer. 2021 Feb;24(1):34-48. doi: 10.4048/jbc.2021.24.e12.ABSTRACTPURPOSE: Receptor-interacting protein 3 (RIP3) is the main initiator of necroptosis. Parkin prevents the formation of the RIP1-RIP3 complex by promoting polyubiquitination of RIP3. However, the mechanism by which necroptosis affects the clinical features of breast cancer and prognosis is not known. Here, we aimed to study the effect of necroptosis on the clinical…
- Clinical Significance of Receptor-Interacting Protein 3 and Parkin, Essential Molecules for Necroptosis, in Breast Cancer February 26, 2021 J Breast Cancer. 2021 Feb;24(1):34-48. doi: 10.4048/jbc.2021.24.e12.ABSTRACTPURPOSE: Receptor-interacting protein 3 (RIP3) is the main initiator of necroptosis. Parkin prevents the formation of the RIP1-RIP3 complex by promoting polyubiquitination of RIP3. However, the mechanism by which necroptosis affects the clinical features of breast cancer and prognosis is not known. Here, we aimed to study the effect of necroptosis on the clinical…
- Clinical Significance of Receptor-Interacting Protein 3 and Parkin, Essential Molecules for Necroptosis, in Breast Cancer February 26, 2021 J Breast Cancer. 2021 Feb;24(1):34-48. doi: 10.4048/jbc.2021.24.e12.ABSTRACTPURPOSE: Receptor-interacting protein 3 (RIP3) is the main initiator of necroptosis. Parkin prevents the formation of the RIP1-RIP3 complex by promoting polyubiquitination of RIP3. However, the mechanism by which necroptosis affects the clinical features of breast cancer and prognosis is not known. Here, we aimed to study the effect of necroptosis on the clinical…
- Clinical Significance of Receptor-Interacting Protein 3 and Parkin, Essential Molecules for Necroptosis, in Breast Cancer February 26, 2021 J Breast Cancer. 2021 Feb;24(1):34-48. doi: 10.4048/jbc.2021.24.e12.ABSTRACTPURPOSE: Receptor-interacting protein 3 (RIP3) is the main initiator of necroptosis. Parkin prevents the formation of the RIP1-RIP3 complex by promoting polyubiquitination of RIP3. However, the mechanism by which necroptosis affects the clinical features of breast cancer and prognosis is not known. Here, we aimed to study the effect of necroptosis on the clinical…
- Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study April 1, 2022 Cancer. 2022 Apr 1. doi: 10.1002/cncr.34208. Online ahead of print.ABSTRACTBACKGROUND: Current guidelines recommend the treatment of hormone receptor-positive breast cancer with aromatase inhibitors (AIs) and tamoxifen in the adjuvant setting. Some observational studies have raised concerns that tamoxifen may be associated with an increased risk of Parkinson disease (PD). However, no studies have directly compared the risk of PD between…